Expert Review of Neurotherapeutics最新文献_第6页

The challenges and opportunities related to the therapeutic use of music in psychiatry. 在精神病治疗中使用音乐的挑战和机遇。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-07-01 Epub Date: 2024-05-27 DOI: 10.1080/14737175.2024.2359429

Hubertus Himmerich, Annie Heiderscheit

引用次数: 0

Risk factors and disease associations in people living with idiopathic intracranial hypertension. 特发性颅内高压患者的风险因素和疾病关联。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-07-01 Epub Date: 2024-05-27 DOI: 10.1080/14737175.2024.2359420

Olivia Potter, Vaishnavi Menon, Susan P Mollan

{"title":"Risk factors and disease associations in people living with idiopathic intracranial hypertension.","authors":"Olivia Potter, Vaishnavi Menon, Susan P Mollan","doi":"10.1080/14737175.2024.2359420","DOIUrl":"10.1080/14737175.2024.2359420","url":null,"abstract":"Introduction: Idiopathic intracranial hypertension is a neurological condition characterized by a raised intracranial pressure and papilledema, leading to chronic headaches and visual disturbances. By recognizing modifiable risk factors and deploying evidence-based interventions, healthcare providers have the potential to mitigate the burden of the disease and improve patient outcomes.Areas covered: It is well known that the condition occurs in predominantly pre-menopausal females who live with obesity particularly in the context of recent weight gain. This review discusses what risk factors may contribute to the metabolic underpinnings of cerebrospinal fluid dysregulation. There are a number of disease associations that are important to screen for as they can alter management.Expert opinion: There is emerging evidence to suggest that idiopathic intracranial hypertension is a systemic metabolic disease and it is unknown what are all the risk factors are that precipitate the condition. Targeting certain hardwired risk factors is unachievable. However, as recent weight gain has been identified as a predominant risk factor for the development of the disease and relapse, modification of body weight should be the primary aim of management. Insightful research into the involvement of the neuroendocrine axis driving cerebrospinal fluid dysregulation now has the potential for the development of therapeutic targets.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"681-689"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141157916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phase-specific strategies and interventions to enhance medication adherence across different phases in ADHD: a systematic review and meta-analysis. 提高多动症患者不同阶段服药依从性的特定策略和干预措施：系统综述和荟萃分析。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-07-01 Epub Date: 2024-06-11 DOI: 10.1080/14737175.2024.2360118

Muhammad Umair Khan, Syed Shahzad Hasan

{"title":"Phase-specific strategies and interventions to enhance medication adherence across different phases in ADHD: a systematic review and meta-analysis.","authors":"Muhammad Umair Khan, Syed Shahzad Hasan","doi":"10.1080/14737175.2024.2360118","DOIUrl":"10.1080/14737175.2024.2360118","url":null,"abstract":"Introduction: This systematic review and meta-analysis assessed the characteristics, types, and impact of interventions to improve adherence to attention-deficit hyperactivity disorder (ADHD) medications within the context of the three phases of adherence, namely, initiation, implementation, and discontinuation.Methods: PubMed, Psychological Information Database, Embase, International Pharmaceutical Abstracts, and Google Scholar were systematically searched for relevant trials using appropriate search terms. Interventions were classified as educational, behavioural, affective, and multifaceted. Data was pooled using odds ratios and proportions.Results: Seventeen studies were included in this review. In a pooled analysis of four RCTs, interventions did not significantly improve medication adherence (OR = 2.32; 95%-Confidence Interval=CI = 0.91-5.90; p = 0.08). In seven non-randomized trials, a pooled proportion of people who adhered to ADHD medication was considerably higher in the intervention group (85%, 95%CI = 78%-91%) than in the control group (47%, 95%CI = 33%-61%). Interventions varied in terms of study design, methods and their impact on different phases of adherence.Conclusions: Despite some promising results, the lack of consideration of phase-specific adherence factors may limit the effectiveness and sustainability of interventions to improve adherence in clinical practice. Future interventions should be phase-specific, guided by factors which are pertinent to each phase. Meanwhile, clinicians should choose or tailor interventions based on individual needs and preferences.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"711-722"},"PeriodicalIF":3.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141300474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Developments in the prediction of cognitive changes following deep brain stimulation in persons with Parkinson's disease. 帕金森病患者接受深部脑刺激后认知变化的预测进展。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-07-01 Epub Date: 2024-05-30 DOI: 10.1080/14737175.2024.2360121

Alexander I Tröster

{"title":"Developments in the prediction of cognitive changes following deep brain stimulation in persons with Parkinson's disease.","authors":"Alexander I Tröster","doi":"10.1080/14737175.2024.2360121","DOIUrl":"10.1080/14737175.2024.2360121","url":null,"abstract":"Introduction: Deep brain stimulation (DBS) is an effective treatment for Parkinson's disease (PD) motor symptoms that improves function and quality of life in appropriately selected patients. Because mild to moderate cognitive declines can follow DBS and impact quality of life in a minority of patients, an important consideration involves the cognitive deficit and its prediction.Areas covered: The author briefly summarizes cognitive outcomes from DBS and reviews in more detail the risks/predictors of post-DBS cognitive dysfunction by mainly focusing on work published between 2018 and 2024 and using comprehensive neuropsychological (NP) evaluations. Most publications concern bilateral subthalamic nucleus (STN) DBS. Comment is offered on challenges and potential avenues forward.Expert opinion: STN DBS is relatively safe cognitively but declines occur especially in verbal fluency and executive function/working memory. Numerous predictors and risk factors for cognitive outcomes have been identified (age and pre-operative neuropsychological status appear the most robust) but precise risk estimates cannot yet be confidently offered. Future studies should employ study center consortia, follow uniform reporting criteria (to be developed), capitalize on advances in stimulation, biomarkers, and artificial intelligence, and address DBS in diverse groups. Advances offer an avenue to investigate the amelioration of cognitive deficits in PD using neuromodulation.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"643-659"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141179167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identification and treatment of surgically-remediable causes of infantile epileptic spasms syndrome. 识别和治疗可通过手术修复的婴儿癫痫痉挛综合征病因。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-07-01 Epub Date: 2024-05-30 DOI: 10.1080/14737175.2024.2360117

Emma Macdonald-Laurs, Winston Dzau, Aaron E L Warren, Matthew Coleman, Cristina Mignone, Sarah E M Stephenson, Katherine B Howell

{"title":"Identification and treatment of surgically-remediable causes of infantile epileptic spasms syndrome.","authors":"Emma Macdonald-Laurs, Winston Dzau, Aaron E L Warren, Matthew Coleman, Cristina Mignone, Sarah E M Stephenson, Katherine B Howell","doi":"10.1080/14737175.2024.2360117","DOIUrl":"10.1080/14737175.2024.2360117","url":null,"abstract":"Introduction: Infantile epileptic spasms syndrome (IESS) is a common developmental and epileptic encephalopathy with poor long-term outcomes. A substantial proportion of patients with IESS have a potentially surgically remediable etiology. Despite this, epilepsy surgery is underutilized in this patient group. Some surgically remediable etiologies, such as focal cortical dysplasia and malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE), are under-diagnosed in infants and young children. Even when a surgically remediable etiology is recognised, for example, tuberous sclerosis or focal encephalomalacia, epilepsy surgery may be delayed or not considered due to diffuse EEG changes, unclear surgical boundaries, or concerns about operating in this age group.Areas covered: In this review, the authors discuss the common surgically remediable etiologies of IESS, their clinical and EEG features, and the imaging techniques that can aid in their diagnosis. They then describe the surgical approaches used in this patient group, and the beneficial impact that early epilepsy surgery can have on developing brain networks.Expert opinion: Epilepsy surgery remains underutilized even when a potentially surgically remediable cause is recognized. Overcoming the barriers that result in under-recognition of surgical candidates and underutilization of epilepsy surgery in IESS will improve long-term seizure and developmental outcomes.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"661-680"},"PeriodicalIF":4.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141179171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current use of neurotoxins for alleviating symptoms of cervical dystonia 目前使用神经毒素缓解颈肌张力障碍症状的情况

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-06-19 DOI: 10.1080/14737175.2024.2368638

Stephen Aradi, Robert A. Hauser

引用次数: 0

Bipolar disorder staging and the impact it has on its management: an update. 躁郁症分期及其对治疗的影响：最新进展。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-06-01 Epub Date: 2024-05-16 DOI: 10.1080/14737175.2024.2355264

Bernardo Dell'Osso, Laura Cremaschi, Monica Macellaro, Rita Cafaro, Nicolaja Girone

{"title":"Bipolar disorder staging and the impact it has on its management: an update.","authors":"Bernardo Dell'Osso, Laura Cremaschi, Monica Macellaro, Rita Cafaro, Nicolaja Girone","doi":"10.1080/14737175.2024.2355264","DOIUrl":"10.1080/14737175.2024.2355264","url":null,"abstract":"Introduction: The longitudinal course of bipolar disorder (BD) is associated with an active process of neuroprogression, characterized by structural brain alterations and progressive functional impairment. In the last decades, a growing need of a standardized staging model for BD arose, with the aim of a more appropriate definition of stage-specific clinical manifestations and the identification of more customized therapeutic tools.Areas covered: The authors review the literature on clinical aspects, neurobiological correlates and treatment issues related to BD progression. Thereafter, they address the definition, constructs, and evolution of the staging concept, focusing on the clinical applications of BD staging models available in literature.Expert opinion: Although several staging models for BD have been proposed to date, their application in clinical practice is still relatively scant. This may have a detrimental impact on the clinical and therapeutic management of BD, in terms of early and proper diagnosis as well as tailored treatment interventions according to the different stages of illness. Future research efforts should tend to the integration of recent insights on neuroimaging and epigenetic markers, toward a standardized and multidimensional staging model.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"565-574"},"PeriodicalIF":4.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140956967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The donepezil transdermal system for the treatment of patients with mild, moderate, or severe Alzheimer's disease: a critical review. 用于治疗轻度、中度或重度阿尔茨海默病患者的多奈哌齐透皮系统：评论性综述。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-06-01 Epub Date: 2024-05-24 DOI: 10.1080/14737175.2024.2355981

Austin Buck, Kayvon Rezaei, Aman Quazi, Gary Goldmeier, Bret Silverglate, George T Grossberg

{"title":"The donepezil transdermal system for the treatment of patients with mild, moderate, or severe Alzheimer's disease: a critical review.","authors":"Austin Buck, Kayvon Rezaei, Aman Quazi, Gary Goldmeier, Bret Silverglate, George T Grossberg","doi":"10.1080/14737175.2024.2355981","DOIUrl":"10.1080/14737175.2024.2355981","url":null,"abstract":"Introduction: Cholinesterase inhibitors, along with memantine, are the mainstay of symptomatic treatment for AD (Alzheimer's disease); however, these medications are typically administered orally, which can be difficult for people with AD and their caregivers.Areas covered: In this drug profile and narrative review, the authors trace the development of the new FDA-approved transdermal donepezil. The authors discuss the studies showing its bioequivalence with the oral formulation, including two double-blinded placebo controlled non-inferiority trials. The authors also compare the patch to the only other transdermal cholinesterase inhibitor on the market, rivastigmine, and highlight the potential advantages and disadvantages between these two treatments.Expert opinion: While the patch is bio-equivalent, it is rather large and may not be affordable for some patients. In addition, there is no high dose (e.g. 23 mg) equivalent. Nevertheless, transdermal donepezil will be useful for people with AD and their caregivers, given its effectiveness and potential convenience.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":"24 6","pages":"607-614"},"PeriodicalIF":4.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141087488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tackling internet gaming disorder: what are the challenges in its treatment? 应对网络游戏障碍：治疗网络游戏障碍面临哪些挑战？

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-06-01 Epub Date: 2024-05-09 DOI: 10.1080/14737175.2024.2349819

Kristyn Zajac, Meredith K Ginley, Lourah M Kelly, Jessica N Flori, Rory A Pfund

引用次数: 0

Profiling tofersen as a treatment of superoxide dismutase 1 amyotrophic lateral sclerosis. 分析托非森治疗超氧化物歧化酶 1 肌萎缩性脊髓侧索硬化症的效果。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-06-01 Epub Date: 2024-05-17 DOI: 10.1080/14737175.2024.2355983

Miguel Oliveira Santos, Mamede de Carvalho

{"title":"Profiling tofersen as a treatment of superoxide dismutase 1 amyotrophic lateral sclerosis.","authors":"Miguel Oliveira Santos, Mamede de Carvalho","doi":"10.1080/14737175.2024.2355983","DOIUrl":"10.1080/14737175.2024.2355983","url":null,"abstract":"Introduction: Amyotrophic lateral sclerosis (ALS) is a rapidly progressive motor neuron disorder with a fatal outcome 3-5 years after disease onset due to respiratory complications. Superoxide dismutase 1 (SOD1) mutations are found in about 2% of all patients. Tofersen is a novel oligonucleotide antisense drug specifically developed to treat SOD1-ALS patients.Areas covered: Our review covers and discusses tofersen pharmacological properties and its phase I/II and III clinical trials results. Other available drugs and their limitations are also addressed.Expert opinion: VALOR study failed to meet the primary endpoint (change in the revised Amyotrophic Lateral Sclerosis Functional Rating Scale score from baseline to week 28, tofersen arm vs. placebo), but a significant reduction in plasma neurofilament light chain (NfL) levels was observed in tofersen arm (60% vs. 20%). PrefALS study has proposed plasma NfL has a potential biomarker for presymptomatic treatment, since it increases 6-12 months before phenoconversion. There is probably a delay between plasma NfL reduction and the clinical benefit. ATLAS study will allow more insights regarding tofersen clinical efficacy in disease progression rate, survival, and even disease onset delay in presymptomatic SOD1 carriers.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"549-553"},"PeriodicalIF":4.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140956968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0